Shares in French biotech Abivax (Euronext Paris: ABVX) were up by more than 150% at times on Tuesday as markets reacted to news of a potentially important HIV breakthrough, albeit with mid-stage results.
The company announced that its lead candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected patients as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs).
"We embrace the deep responsibility we have towards all HIV patients and the HIV community in driving this unique compound forward"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze